全球生物製藥契約製造市場規模、佔有率、趨勢和成長分析報告（2026-2034）

預計生物製藥契約製造市場將從 2025 年的 497.6 億美元成長到 2034 年的 1,319 億美元，2026 年至 2034 年的複合年成長率為 11.44%。

由於對生物製藥、生物相似藥和複雜治療產品的需求不斷成長，全球生物製藥契約製造市場正在快速擴張。製藥公司擴大將生產流程外包給契約製造組織（CMO），以降低成本並簡化營運。這一趨勢顯著推動了各個地區市場的成長。

關鍵成長要素包括慢性病盛行率上升、研發投入增加、生物製藥生產日益複雜。契約製造生產商是重要的合作夥伴，可提供專業知識、先進技術和法規支援。此外，對靈活且擴充性的生產能力的需求不斷成長，也進一步推動了市場需求。

未來，由於生物製程的創新和個人化醫療的興起，市場預計將顯著成長。基因療法和先進生物製藥的發展將為合約生產企業（CMO）創造新的機會。隨著製藥公司持續專注於創新和效率提升，契約製造仍將是該產業至關重要的策略要素。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球生物製藥契約製造市場：依來源分類

• 市場分析、洞察與預測
• 哺乳動物起源
• 非哺乳動物

第5章：全球生物製藥契約製造市場：依服務類型分類

• 市場分析、洞察與預測
• 製程開發
• 填充和表面處理工程
• 分析和品管(QC) 測試
• 包裝和標籤
• 其他

第6章 全球生物製藥契約製造市場：依藥物類型分類

• 市場分析、洞察與預測
• 生物製藥
• 生物相似藥

第7章 全球生物製藥契約製造市場：按類型分類

• 市場分析、洞察與預測
• 原料藥
• 已完成的藥品

第8章：全球生物製藥契約製造市場：依企業規模分類

• 市場分析、洞察與預測
• 臨床階段
• 商業

第9章：全球生物製藥契約製造市場：依治療領域分類

• 市場分析、洞察與預測
• 腫瘤學
• 自體免疫疾病
• 感染疾病
• 心血管疾病
• 代謝性疾病
• 神經病學
• 其他

第10章：全球生物製藥契約製造市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第11章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第12章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Boehringer Ingelheim GmbH
  • Lonza
  • Inno Biologics Sdn Bhd
  • Rentschler Biotechnologie GmbH
  • JRS PHARMA
  • AGC Biologics
  • ProBioGen
  • FUJIFILM Diosynth Biotechnologies USA Inc
  • Toyobo Co. Ltd
  • Samsung Biologics
  • Thermo Fisher Scientific Inc
  • Binex Co. Ltd
  • WuXi Biologics
  • AbbVie Inc

The Biopharmaceuticals Contract Manufacturing Market size is expected to reach USD 131.90 Billion in 2034 from USD 49.76 Billion (2025) growing at a CAGR of 11.44% during 2026-2034.

The global biopharmaceuticals contract manufacturing market is witnessing rapid expansion due to the increasing demand for biologics, biosimilars, and complex therapeutic products. Pharmaceutical companies are increasingly outsourcing manufacturing processes to contract manufacturing organizations (CMOs) to reduce costs and streamline operations. This trend has significantly contributed to the growth of the market across various regions.

Major growth drivers include the rising prevalence of chronic diseases, increased investment in research and development, and the complexity of biologic drug production. Contract manufacturers provide specialized expertise, advanced technologies, and regulatory support, making them valuable partners. Additionally, the need for flexible and scalable production capabilities is further boosting market demand.

Looking ahead, the market is poised for substantial growth driven by innovations in bioprocessing and the emergence of personalized medicine. The development of gene therapies and advanced biologics will create new opportunities for CMOs. As pharmaceutical companies continue to focus on innovation and efficiency, contract manufacturing will remain a key strategic component in the industry.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Source

• Mammalian
• Non-mammalian

By Service

• Process Development
• Fill & Finish Operations
• Analytical & QC studies
• Packaging & Labelling
• Others

By Drug Type

• Biologics
• Biosimilars

By Type

• Drug Substance
• Finished Drug Product

By Scale of Operation

• Clinical
• Commercial

By Therapeutic Area

• Oncology
• Autoimmune Diseases
• Infectious Diseases
• Cardiovascular Diseases
• Metabolic Diseases
• Neurology
• Others

COMPANIES PROFILED

• Boehringer Ingelheim GmbH, Lonza, Inno Biologics Sdn Bhd, Rentschler Biotechnologie GmbH, JRS PHARMA, AGC Biologics, ProBioGen, FUJIFILM Diosynth Biotechnologies USA Inc, Toyobo Co Ltd, Samsung Biologics, Thermo Fisher Scientific Inc, Binex Co Ltd, WuXi Biologics, AbbVie Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: BY SOURCE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Source
• 4.2. Mammalian Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Non-mammalian Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: BY SERVICE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Service
• 5.2. Process Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Fill & Finish Operations Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Analytical & QC studies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Packaging & Labelling Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Drug Type
• 6.2. Biologics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Biosimilars Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: BY TYPE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Type
• 7.2. Drug Substance Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Finished Drug Product Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: BY SCALE OF OPERATION 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Scale Of Operation
• 8.2. Clinical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Commercial Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast Therapeutic Area
• 9.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. Autoimmune Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.5. Cardiovascular Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.6. Metabolic Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.7. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: BY REGION 2022-2034 (USD MN)

• 10.1. Regional Outlook
• 10.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.2.1 By Source
  • 10.2.2 By Service
  • 10.2.3 By Drug Type
  • 10.2.4 By Type
  • 10.2.5 By Scale Of Operation
  • 10.2.6 By Therapeutic Area
  • 10.2.7 United States
  • 10.2.8 Canada
  • 10.2.9 Mexico
• 10.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.3.1 By Source
  • 10.3.2 By Service
  • 10.3.3 By Drug Type
  • 10.3.4 By Type
  • 10.3.5 By Scale Of Operation
  • 10.3.6 By Therapeutic Area
  • 10.3.7 United Kingdom
  • 10.3.8 France
  • 10.3.9 Germany
  • 10.3.10 Italy
  • 10.3.11 Russia
  • 10.3.12 Rest Of Europe
• 10.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.4.1 By Source
  • 10.4.2 By Service
  • 10.4.3 By Drug Type
  • 10.4.4 By Type
  • 10.4.5 By Scale Of Operation
  • 10.4.6 By Therapeutic Area
  • 10.4.7 India
  • 10.4.8 Japan
  • 10.4.9 South Korea
  • 10.4.10 Australia
  • 10.4.11 South East Asia
  • 10.4.12 Rest Of Asia Pacific
• 10.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.5.1 By Source
  • 10.5.2 By Service
  • 10.5.3 By Drug Type
  • 10.5.4 By Type
  • 10.5.5 By Scale Of Operation
  • 10.5.6 By Therapeutic Area
  • 10.5.7 Brazil
  • 10.5.8 Argentina
  • 10.5.9 Peru
  • 10.5.10 Chile
  • 10.5.11 Rest of Latin America
• 10.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.6.1 By Source
  • 10.6.2 By Service
  • 10.6.3 By Drug Type
  • 10.6.4 By Type
  • 10.6.5 By Scale Of Operation
  • 10.6.6 By Therapeutic Area
  • 10.6.7 Saudi Arabia
  • 10.6.8 UAE
  • 10.6.9 Israel
  • 10.6.10 South Africa
  • 10.6.11 Rest of the Middle East And Africa

Chapter 11. COMPETITIVE LANDSCAPE

• 11.1. Recent Developments
• 11.2. Company Categorization
• 11.3. Supply Chain & Channel Partners (based on availability)
• 11.4. Market Share & Positioning Analysis (based on availability)
• 11.5. Vendor Landscape (based on availability)
• 11.6. Strategy Mapping

Chapter 12. COMPANY PROFILES OF GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Company Profiles
  • 12.2.1 Boehringer Ingelheim GmbH
  • 12.2.2 Lonza
  • 12.2.3 Inno Biologics Sdn Bhd
  • 12.2.4 Rentschler Biotechnologie GmbH
  • 12.2.5 JRS PHARMA
  • 12.2.6 AGC Biologics
  • 12.2.7 ProBioGen
  • 12.2.8 FUJIFILM Diosynth Biotechnologies U.S.A. Inc
  • 12.2.9 Toyobo Co. Ltd
  • 12.2.10 Samsung Biologics
  • 12.2.11 Thermo Fisher Scientific Inc
  • 12.2.12 Binex Co. Ltd
  • 12.2.13 WuXi Biologics
  • 12.2.14 AbbVie Inc